TY  - JOUR
AU  - Krilaviciute, Agne
AU  - Kaaks, Rudolf
AU  - Seibold, Petra
AU  - de Vrieze, Maxime
AU  - Lakes, Jale
AU  - Radtke, Jan Philipp
AU  - Kuczyk, Markus
AU  - Harke, Nina N
AU  - Debus, Jürgen
AU  - Fink, Christoph
AU  - Herkommer, Kathleen
AU  - Gschwend, Jürgen E
AU  - Meissner, Valentin H
AU  - Benner, Axel
AU  - Kristiansen, Glen
AU  - Hadaschik, Boris
AU  - Arsov, Christian
AU  - Schimmöller, Lars
AU  - Antoch, Gerald
AU  - Giesel, Frederik L
AU  - Makowski, Marcus
AU  - Wacker, Frank
AU  - Schlemmer, Heinz-Peter
AU  - Becker, Nikolaus
AU  - Albers, Peter
TI  - Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
JO  - European urology
VL  - 86
IS  - 6
SN  - 0302-2838
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2024-01039
SP  - 493-500
PY  - 2024
N1  - #EA:C130#LA:C130# / 2024 Dec;86(6):493-500
AB  - Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55-60 yr.To identify men at age 45 yr with a low risk of PCa.A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen (PSA) starting in young men (PROBASE).PSA measurements starting at the age of 45 yr.The incidence of PCa within 5 yr was assessed in men with screen-negative baseline PSA <1.5 ng/ml compared with those with PSA 1.5-≤3.0 ng/ml.Of 23301 men who received a first PSA test at age 45 yr, 0.79
KW  - Low risk (Other)
KW  - Prostate cancer (Other)
KW  - Prostate-specific antigen (Other)
KW  - Screening (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38749854
DO  - DOI:10.1016/j.eururo.2024.04.030
UR  - https://inrepo02.dkfz.de/record/290221
ER  -